Internal competition may motivate worker effort, yet the benefits of competition may depend
critically on workers’ relative abilities: large skill differences may reduce efforts. I use panel …

Background Ibrutinib has been approved by the Food and Drug Administration for the
treatment of patients with untreated chronic lymphocytic leukemia (CLL) since 2016 but has not …

In a phase 1 trial, idelalisib (GS-1101, CAL-101), a selective inhibitor of the lipid kinase
PI3Kδ, was evaluated in 54 patients with relapsed/refractory chronic lymphocytic leukemia (CLL) …

We describe the landscape of somatic genomic alterations based on multidimensional and
comprehensive characterization of more than 500 glioblastoma tumors (GBMs). We identify …

Background New treatments have improved outcomes for patients with relapsed chronic
lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a …

Background In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma
(SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are …

Clonal evolution is a key feature of cancer progression and relapse. We studied intratumoral
heterogeneity in 149 chronic lymphocytic leukemia (CLL) cases by integrating whole-…

Background In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton’s tyrosine kinase
(BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater specificity, …

Background The somatic genetic basis of chronic lymphocytic leukemia, a common and
clinically heterogeneous leukemia occurring in adults, remains poorly understood. Methods We …

… Jennifer Brown reports receiving nonfinancial support from Novo Nordisk, and personal
fees from Bausch Health, Dietitians of Canada, Obesity Canada and the Canadian Association …